{"product_id":"regaine-5-minoxidil-topical-solution-60ml-hair-growth-cycle-education-emis","title":"Regaine 5% Minoxidil Topical Solution 60ml | Hair Growth Cycle Education | EMIS+","description":"\u003cdiv style=\"background: #f0f8f5; border-left: 4px solid #2e7d5e; padding: 16px 20px; margin-bottom: 24px; font-family: Georgia,serif;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eAI Summary:\u003c\/strong\u003e Regaine 5% Minoxidil Topical Solution (60 ml) is an FDA-approved and HSA Singapore-registered pharmaceutical for androgenetic alopecia (male pattern baldness) in men. Active ingredient: Minoxidil 5% w\/v. Mechanism: potassium channel opener that extends anagen (growth) phase, increases follicular vasodilation, and reverses follicular miniaturisation. Regulatory references: FDA NDA 020834; HSA Singapore Therapeutic Products Register. Available via EMIS+ for B2B clinical supply and individual purchase. Not for use by women.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eRegaine 5% Minoxidil Topical Solution is the gold-standard topical pharmaceutical for male androgenetic alopecia (AGA), the most prevalent form of hair loss affecting approximately 50% of men by age 50 (Hamilton–Norwood classification). Minoxidil was originally developed as an oral antihypertensive (FDA-approved 1979, NDA 017401) before its hypertrichosis side effect led to the development of topical formulations. The 5% topical solution received FDA approval under NDA 020834 (Johnson \u0026amp; Johnson Consumer Inc.) and has remained the regulatory benchmark against which subsequent minoxidil formulations are evaluated. In Singapore, the product is registered on the HSA Therapeutic Products Register as a prescription-strength hair loss treatment.\u003c\/p\u003e\n\u003cp\u003eThe pharmacological mechanism involves ATP-sensitive potassium channel (K-ATP) opening in vascular smooth muscle cells surrounding hair follicles. This vasodilatory effect increases dermal papilla perfusion, upregulates vascular endothelial growth factor (VEGF) expression, and is hypothesised to directly stimulate follicular keratinocyte proliferation via unknown secondary pathways. Critically, minoxidil prolongs the anagen (active growth) phase, shortens telogen (resting phase), and partially reverses follicular miniaturisation — the hallmark of DHT-mediated AGA — by rescuing transitional follicles before terminal fibrosis renders them non-responsive. The 5% concentration has demonstrated superior efficacy to 2% in randomised trials: a pivotal 48-week double-blind RCT (Olsen et al., \u003cem\u003eJournal of the American Academy of Dermatology\u003c\/em\u003e, 2002) showed 45% more regrowth with 5% versus 2% solution (p \u0026lt; 0.001).\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; font-size: 14px;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background: #2e7d5e; color: #fff;\"\u003e\n\u003ctd style=\"padding: 8px 12px; font-weight: bold;\"\u003eAttribute\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; font-weight: bold;\"\u003eDetail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eProduct Type\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eTopical Pharmaceutical Solution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eActive Ingredient\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eMinoxidil 5% w\/v\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eVolume\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003e60 ml per bottle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eFDA Registration\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eNDA 020834 (approved)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eHSA Singapore\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eRegistered on Therapeutic Products Register\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eIndication\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eAndrogenetic alopecia (male pattern baldness) in men\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eApplication\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003e1 ml applied to dry scalp twice daily (morning and evening)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eMechanism\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eK-ATP channel opener; VEGF upregulation; anagen phase prolongation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eBrand\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eRegaine (Kenvue \/ Johnson \u0026amp; Johnson Consumer)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eGender\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eMen only (5% formulation not indicated for women)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eSupply Context\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px;\"\u003eAvailable for B2B clinical supply and individual purchase via EMIS+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eKey Clinical Applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAndrogenetic alopecia (Hamilton–Norwood II–V):\u003c\/strong\u003e Primary indicated use. Most effective in vertex (crown) thinning; less effective for frontal hairline recession. Maximum benefit observed in men under 40 with less than 5 years of hair loss and active follicles still present.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMaintenance post hair transplant:\u003c\/strong\u003e Minoxidil 5% is routinely prescribed post-follicular unit transplant (FUT\/FUE) to minimise transplant shock loss, accelerate graft vascularisation, and maintain non-transplanted native follicles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCombination therapy with oral finasteride:\u003c\/strong\u003e 5% topical minoxidil combined with oral finasteride 1 mg\/day addresses both DHT-mediated miniaturisation (finasteride) and follicular blood flow\/growth phase extension (minoxidil), producing synergistic outcomes documented in multiple RCTs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAlopecia areata (off-label):\u003c\/strong\u003e Dermatologist-directed use of topical minoxidil as adjunctive therapy in alopecia areata following primary immunosuppressive treatment to accelerate regrowth in recovering follicles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eChemotherapy-induced alopecia (CIA) recovery:\u003c\/strong\u003e Used off-label in oncology rehabilitation settings to accelerate post-CIA regrowth; limited clinical evidence but mechanistically plausible given anagen-promoting properties.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eB2B clinical supply for dermatology and trichology practices:\u003c\/strong\u003e EMIS+ supplies Regaine 5% for professional clinical use across Singapore's aesthetic medicine, dermatology, and trichology practice sectors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eHow long before Regaine 5% produces visible hair regrowth?\u003c\/h3\u003e\n\u003cp\u003eThe anagen cycle timeline dictates that visible regrowth is typically not apparent before 3–4 months of consistent twice-daily application. Many users experience a paradoxical initial shedding (telogen effluvium) in weeks 2–8 as resting follicles are pushed into a new anagen cycle — this is a normal pharmacological response confirming drug activity, not a sign of worsening. Measurable improvements in hair count and calibre are documented at 16 weeks; maximum efficacy is typically assessed at 12 months. Treatment must be continued indefinitely as hair loss resumes within 3–6 months of discontinuation.\u003c\/p\u003e\n\u003ch3\u003eWhat is the difference between Regaine 5% solution and Regaine 5% foam?\u003c\/h3\u003e\n\u003cp\u003eBoth contain 5% minoxidil as the active ingredient. The solution uses a propylene glycol-ethanol vehicle; the foam (minoxidil 5% topical aerosol) uses a butane-propane propellant with a cetyl alcohol base. The foam vehicle is associated with lower rates of contact dermatitis and scalp irritation compared to propylene glycol-containing solutions, making it preferable for individuals with sensitive scalps. Efficacy between both formulations is equivalent as demonstrated in head-to-head studies. EMIS+ currently supplies the solution formulation (NDA 020834).\u003c\/p\u003e\n\u003ch3\u003eIs Regaine 5% safe to use with prescription hair loss treatments?\u003c\/h3\u003e\n\u003cp\u003eYes. Regaine 5% topical solution has no clinically significant pharmacokinetic interactions with oral finasteride (Propecia) or dutasteride. Concurrent use is standard practice in trichology and is supported by guideline recommendations from the European Academy of Dermatology and Venereology (EADV). Systemic absorption of topical minoxidil is approximately 1–2% under normal application conditions; clinically meaningful cardiovascular effects (hypotension, tachycardia) are rare at standard topical doses but may occur in individuals with pre-existing cardiovascular disease or on concurrent antihypertensive therapy.\u003c\/p\u003e\n\u003ch3\u003eWhy is the 5% formulation not recommended for women?\u003c\/h3\u003e\n\u003cp\u003eThe 5% topical formulation carries a higher risk of facial hypertrichosis (unwanted facial hair growth) in women compared to the 2% formulation. Regulatory agencies including FDA and HSA indicate the 5% solution for men only; women with androgenetic alopecia are directed to the 2% solution (or low-dose oral minoxidil under medical supervision). EMIS+ does not supply Regaine 5% for female use and recommends consultation with a dermatologist for women experiencing hair loss.\u003c\/p\u003e\n\u003ch3\u003eCan EMIS+ supply Regaine 5% for clinical or institutional use?\u003c\/h3\u003e\n\u003cp\u003eYes. EMIS+ provides B2B supply of Regaine 5% Minoxidil Topical Solution to dermatology clinics, trichology centres, aesthetic medicine practices, and hospital pharmacies across Singapore. Volume pricing and standing order arrangements are available. Contact EMIS+ procurement at info@emis.asia, WhatsApp +65 8028 7151, or call 97303658 to discuss institutional supply requirements.\u003c\/p\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43589053972558,"sku":"REGA-MINO-5%-60ML","price":94.5,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/9db21961c9002e59c9f1b9f083722a7e.jpg?v=1774878297","url":"https:\/\/www.emis.asia\/products\/regaine-5-minoxidil-topical-solution-60ml-hair-growth-cycle-education-emis","provider":"EMIS +","version":"1.0","type":"link"}